Full-Time

Vice President Clinical Development

Clinical Development

Posted on 9/19/2025

Alector

Alector

51-200 employees

Biopharmaceutical R&D for neurodegenerative therapies

Compensation Overview

$370k - $415k/yr

Remote in USA

Remote

Category
Medical, Clinical & Veterinary (1)
Required Skills
LLM
Requirements
  • MD, MD/PhD with at least 10 years of clinical drug development experience.
  • Proven track record leading programs in rare diseases and CNS, or alternatively, in neurodegenerative disease.
  • Demonstrated success bringing therapies through late-stage development, US FDA interactions and filing, and drug launch. You have been the point-person leading filings with the FDA.
  • Experience working independently and cross-functionally in fast-paced, matrixed environments. You are a team player and know how to influence your cross-functional colleagues.
  • Active user of large language models (LLMs) with a strong interest in evolving AI applications in clinical development and commercialization-readiness.
Responsibilities
  • Serve as lead clinical expert for our Phase 3 FTD program following data readout, driving all clinical strategies and partnering on regulatory activities to enable filing!
  • Lead strategic and operational engagement with the US FDA, including participation in key meetings and authorship of major regulatory submissions.
  • Own the clinical development plan from late-stage study execution through potential BLA filing and NDA approval.
  • Provide clinical insights that guide program decisions, ensuring scientific rigor, patient safety, and regulatory compliance at every step.
  • Integrate innovative technologies—including AI—to accelerate timelines and improve decision-making across development stages!

Alector is a biopharmaceutical company that develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It uses insights from immunology, neurology, and human genetics to create medicines that help the body heal itself. The company focuses on researching and developing novel therapeutic candidates, mainly through early-stage clinical trials to quickly gather disease-specific data and improve the chances of success. Revenue and funding come from partnerships, grants, and eventual product commercialization. Alector aims to advance treatments for unmet medical needs in neurodegenerative diseases by pursuing a pipeline that combines scientific findings with strategic drug development.

Company Size

51-200

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • AL037/AL137-ABC anti-amyloid antibody targets validated epitope with reduced ARIA risk versus competitors.
  • Cash position of $206.5 million funds operations through 2027 and preclinical pipeline advancement.
  • Analyst consensus price target 48% above current stock price signals potential undervaluation opportunity.

What critics are saying

  • AL002 Phase 2 failure and GSK latozinemab efficacy stumble eliminate two major clinical assets.
  • Hercules Capital debt covenants trigger default from Q1 2026 revenue miss, forcing $10M repayment.
  • 13% workforce layoff signals cash constraints and accelerates talent exodus to better-funded competitors.

What makes Alector unique

  • Proprietary Alector Brain Carrier technology enables blood-brain barrier penetration for siRNA and protein therapeutics.
  • Genetically-validated target selection from human genetics, neuroscience, and immunology insights reduces clinical failure risk.
  • AL050 GCase enzyme replacement therapy addresses GBA mutations in Parkinson's and Lewy body dementia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

3%

2 year growth

6%
Yahoo Finance
Feb 25th, 2026
Alector beats Q4 expectations with $6.2M revenue, narrows loss to 34 cents per share

Alector, a South San Francisco-based biotechnology company, reported a fourth-quarter loss of $37.3 million, or 34 cents per share, beating analyst expectations of a 39-cent loss. The company posted revenue of $6.2 million, exceeding forecasts of $3.1 million from three analysts surveyed by Zacks Investment Research. For the full year, Alector's loss widened to $142.9 million, or $1.39 per share, with revenue of $21 million. The company's shares closed at $2.39 on Wednesday, up from $1.77 a year earlier.

GlobeNewswire
Jun 3rd, 2025
Alector To Participate In The Goldman Sachs 46Th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.About AlectorAlector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline

Stock Titan
May 6th, 2025
Alector to Participate in Upcoming Healthcare Conferences

Additionally, Alector will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025, at 12:00 p.m. ET.

ITTBioMed
Apr 2nd, 2025
New breakthroughs in early-onset dementia: progranulin therapies show promise

In another strategy, Alector, in collaboration with GSK, is developing the monoclonal antibody latozinemab (AL001), which works by blocking progranulin degradation to boost its availability.

BioSpace
Mar 25th, 2025
Alector Cuts Staff Again, This Time Laying Off 13% of Workforce

As part of cost-cutting efforts, Alector is letting go of about 25 people as it focuses on advancing its preclinical and research pipeline.

INACTIVE